PMV Pharmaceuticals, Inc. (PMVP) has a negative trailing P/E of -0.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 8.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -113.55%, forward earnings yield 11.56%.
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -6.5 | 0.00 | -2.46 | 0.00 | - |
| 2019 | -63.6 | 0.71 | -22.89 | 0.00 | - |
| 2020 | -80.0 | -0.26 | 7.67 | 0.00 | - |
| 2021 | -18.0 | 0.39 | 3.38 | 0.00 | - |
| 2022 | -5.4 | -0.21 | 1.61 | 0.00 | - |
| 2023 | -2.2 | 0.20 | 0.66 | 0.00 | - |
| 2024 | -1.3 | 0.06 | 0.44 | 0.00 | - |
| 2025 | -0.8 | -0.03 | 0.63 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.56 | $0.00 | $-17.54M | - |
| 2019 | $-0.59 | $0.00 | $-25.35M | - |
| 2020 | $-2.40 | $0.00 | $-34.44M | - |
| 2021 | $-1.28 | $0.00 | $-57.85M | - |
| 2022 | $-1.61 | $0.00 | $-73.32M | - |
| 2023 | $-1.44 | $0.00 | $-68.96M | - |
| 2024 | $-1.14 | $0.00 | $-58.71M | - |
| 2025 | $-1.48 | $0.00 | $-77.74M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.57 | $-1.62 – $-1.49 | $2.93M | $2.93M – $2.93M | 2 |
| 2027 | $-1.16 | $-1.21 – $-1.10 | $2.96M | $2.96M – $2.96M | 2 |
| 2028 | $-0.83 | $-0.83 – $-0.83 | $24.3M | $24.3M – $24.3M | 1 |
| 2029 | $-0.58 | $-0.58 – $-0.58 | $55.81M | $55.81M – $55.81M | 1 |
| 2030 | $0.17 | $0.17 – $0.17 | $155.36M | $155.36M – $155.36M | 1 |
